SYDNEY, Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the ...
Effect of TT-816, a novel immune response modifier targeting cannabinoid CB2 receptor, on antitumor immunity and cancer growth. Antitumor mechanisms of OncoTherad (MRB-CFI-1) nanoimmunotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results